Patents by Inventor Kirti Valia

Kirti Valia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRANSDERMAL PATCH
    Publication number: 20230218538
    Abstract: The present invention relates to a transdermal patch for the for the transdermal administration of oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.
    Type: Application
    Filed: March 16, 2023
    Publication date: July 13, 2023
    Inventor: Kirti VALIA
  • TRANSDERMAL PATCH
    Publication number: 20190328681
    Abstract: The present invention relates to an abuse deterrent transdermal patch, particularly transdermal patch for the transdermal administration of an opioid analgesic. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.
    Type: Application
    Filed: January 18, 2017
    Publication date: October 31, 2019
    Inventor: Kirti VALIA
  • TRANSDERMAL PATCH
    Publication number: 20190022024
    Abstract: The present invention relates to an abuse deterrent transdermal patch, particularly transdermal patch for the transdermal administration of oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.
    Type: Application
    Filed: January 18, 2017
    Publication date: January 24, 2019
    Inventor: Kirti VALIA
  • TRANSDERMAL PATCH
    Publication number: 20190022025
    Abstract: The present invention relates to a transdermal patch for the for the transdermal administration of oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.
    Type: Application
    Filed: January 18, 2017
    Publication date: January 24, 2019
    Inventor: Kirti VALIA
  • Loratadine transdermal device and methods
    Patent number: 9259397
    Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: February 16, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • Felodipine transdermal device and methods
    Patent number: 7018649
    Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: March 28, 2006
    Assignee: Euro-Celtique, S.A.
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • Wound treatment patch for alleviating pain
    Publication number: 20050255150
    Abstract: Methods and topical patches for outpatient treatment of moderate to severe pain with an opioid, for example, the pain caused by surgically closed wounds. The methods and patches of the invention comprise: (1) a local-anesthetic component for local delivery of a local anesthetic; and (2) an opioid component for transdermal delivery of an opioid. The synergistic combination of a local anesthetic and an opioid provides effective relief of moderate to severe pain at lower opioid doses than current opioid treatments.
    Type: Application
    Filed: April 25, 2005
    Publication date: November 17, 2005
    Inventors: Douglas Cassel, Kirti Valia
  • Terazosin transdermal device and methods
    Publication number: 20050064022
    Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
    Type: Application
    Filed: October 23, 2002
    Publication date: March 24, 2005
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • Terazosin transdermal device & methods
    Publication number: 20050031678
    Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
    Type: Application
    Filed: September 20, 2004
    Publication date: February 10, 2005
    Applicant: Euro-Celtique S.A
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia